Feb 13, 2025 | Press Release
In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers in Norway—a trend we expect...
Feb 5, 2025 | Press Release
AFYX Therapeutics is a growing and we have two exciting job opportunities inside Finance & Accounting and Office & Warehouse Administration, respectively. See job posts directly on LInkedIn: Financial Accountant, Copenhagen Area (Hørsholm) – Application...
Jan 13, 2025 | Press Release
Hørsholm, Denmark – January 13, 2025 AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing innovative treatments for Head and Neck Cancer to the French market. Under this collaboration, Cevidra will serve as the local...
Jan 6, 2025 | Press Release
Hørsholm, Denmark – January 6, 2025 Er-Kim and AFYX Therapeutics A/S announced today a distribution and sales collaboration for two AFYX products. The two companies have entered a mutual sales and distribution collaboration where Er-Kim will sell and distribute the...
Dec 19, 2024 | Press Release
Copenhagen, Denmark – December 19, 2024 AFYX Therapeutics A/S, a pioneering Danish biopharmaceutical company specializing in reversed innovation and the repurposing of established pharmaceutical substances, has successfully raised DKK 25 million in its latest funding...
Apr 15, 2024 | Press Release
Hørsholm, Denmark, April 15, 2024 After our recent Annual General Meeting the BOD has now in cooperation with the CEO completed an internal financing round to secure the financial basis for the transformation of our company to become an international growth and...
